This neurology update summarises key points on caring for people with epilepsy during the COVID-19 pandemic.

Seizures appear to be a rare feature of COVID-19. Avoiding unintentional antiseizure medicine withdrawal during the COVID-19 pandemic is a potential challenge for people with epilepsy.

The EAN BrainChallenge also went virtual – as a four-day online quiz.

The European Medicines Agency (EMA) is contributing to global efforts to save lives during the COVID-19 pandemic.

EBRA launches 3rd call for clusters

EAN signed a Memorandum of Understanding with EPNS – European Paediatric Neurology Society joining forces to promote optimal cooperation in Europe between both societies.

Dr. Thomas Jenkins interviews Dr. benedetta Bodini.

BioMed Alliance Board Members publish an article outlining the need for cooperation.

Alzheimer Europe’s 30th Annual Conference #30AEC, which was planned to take place in Bucharest, will now be a virtual conference, under the banner “Dementia in a changing world”

In this paper recently published in Nature Medicine, Leung et al. aimed to explore the importance of respiratory droplet and aerosol routes of transmission with a particular focus on coronaviruses, influenza viruses and rhinoviruses.

In this paper recently published in Annals of Neurology, Pilotto et al., described the case of a 60-year old subject with SARS-CoV-2 infection but only mild respiratory abnormalities who developed akinetic mutism due to encephalitis.

In this paper recently published in Epilepsia, Aledo-Serrano et al. evaluated the impact of the pandemic on patients with genetic, developmental and epileptic encephalopathies (DEEs) and their caregivers in Spain.

In this retrospective, multicentre study, the author systematically characterised neurological symptoms and neuroimaging features in hospitalised COVID-19 patients from multiple institutions in Italy.

In this systematic review and meta-analysis, the authors analysed studies or preprints reporting data on the psychiatric and neuropsychiatric presentations of individuals with suspected or laboratory-confirmed coronavirus infection (SARS coronavirus, MERS coronavirus, or SARS coronavirus 2).